WLWeishan Li

Weishan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weishan Li has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies

    by Simon Kang Seng Ting, Seyed Ehsan Saffari, Stella Jinran Zhan, Tushar Divikar Gosavi, Shahul Hameed, Weishan Li, Jinesh Mukesh Shah, Shawn Zhi Zheng Lin, Jingwei Sim, Hui Jin Chiew, et al.

    Seizures are a recognized comorbidity in dementia, with varying prevalence across Alzheimer disease (AD) and dementia with Lewy bodies (DLBs). Although previous studies have demonstrated an increased seizure risk in AD, the neuropathologic substrates underlying seizure susceptibility-particularly across dementia subtypes-remain incompletely understood. We aimed to identify distinct clinicopathologic correlates of clinically active seizures in AD and DLB using a large autopsy-confirmed cohort. We conducted a retrospective cohort study using data from the National Alzheimer's Coordinating Center (2005-December 2022). Autopsy-confirmed AD and DLB cases were included. Individuals with a history of stroke or traumatic brain injury were excluded. The primary outcome was clinically active seizures, defined as seizures occurring within 3 years before or after the diagnosis of dementia. Neuropathologic exposures included Braak stage, cerebral amyloid angiopathy (CAA), frontotemporal lobar degeneration, and vascular pathologies. Multivariable logistic regression models were used to examine associations between pathologic features and seizure occurrence, adjusting for relevant demographic covariates. A total of 3,498 participants were included, comprising 3,040 with AD (mean age, 73.4 years; 48.5% female) and 458 with DLB (mean age, 75.1 years; 31.4% female). Active seizures were identified in 174 participants with AD (5.7%) and 13 with DLB (2.8%). In AD, Braak stage VI (vs V) was associated with higher odds of active seizures (adjusted odds ratio [OR], 1.81; 95% CI 1.20-2.82; p = 0.007), as was moderate to severe CAA (adjusted OR, 1.38; 95% CI 1.01-1.90; p = 0.045). In DLB, AD-related pathologic features were not associated with seizures. By contrast, vascular pathology was significantly associated with seizure occurrence, including microinfarcts (adjusted OR, 5.11; 95% CI 1.64-16.4; p = 0.005) and infarcts (adjusted OR, 4.11; 95% CI 1.27-12.9; p = 0.015). In this autopsy-confirmed cohort, seizure susceptibility was associated with advanced tau pathology and CAA in AD. In DLB, exploratory analyses suggested a possible association between vascular pathology and seizures; however, these findings should be interpreted cautiously. Overall, the results support potentially distinct pathologic contributions to seizure susceptibility across dementia subtypes. Limitations include the use of advanced-stage pathologic samples, which may limit generalizability to earlier disease stages.


  • Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration

    by Simon Kang Seng Ting, Sean Asahara Thio, Ke Cao, Shahul Hameed, Weishan Li, Jinesh Mukesh Shah, Shawn Lin, Jingwei Sim, Hui Jin Chiew, Kok Pin Ng, et al.

    Objectives Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Methods Data were obtained from the National Alzheimer’s Coordinating Center (NACC) database (2005–March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Results Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20–30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer’s disease. Conclusions A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.


  • Open Access

    An Ultra-Brief Informant Questionnaire for Case Finding of Cognitive Impairment Across Diverse Literacy: Diagnostic Accuracy Study

    by Tau Ming Liew, King Fan Yip, Kaavya Narasimhalu, Simon Kang Seng Ting, Weishan Li, Sze Yan Tay, Way Inn Koay

    Background: Undiagnosed cognitive impairment poses a global challenge, prompting recent interest in ultra-brief screening questionnaires (comprising assistance with medications and worry about cognition ), plus age and years of education. It demonstrated excellent performance in detecting MCI/dementia (AUC 85%, 95% CI 80%‐90%), significantly better ( P =.003) than a nested baseline model (comprising age and years of education; AUC 78%, 95% CI 73%‐83%). In contrast, the AD8 had an AUC of 76% (95% CI 70%‐83%), not significantly different ( P> .99) from the baseline model. The questionnaire’s performance was consistent across education subgroups and varying prevalence scenarios. Two optimal cutoffs were used—the lower cutoff provided 80% sensitivity and 96% negative predictive value, and the upper cutoff provided 99% specificity and 81% positive predictive value. A web-based calculator is available for public use. Conclusions: This ultra-brief questionnaire enables rapid screening for cognitive impairment (in <1 min) by family members or as part of community geriatric assessments. Its excellent performance across literacy levels supports its utility for case finding in diverse populations, including underserved communities and lower- and middle-income countries.


  • Open Access

    PENSIEVE-AI a brief cognitive test to detect cognitive impairment across diverse literacy

    by Tau Ming Liew, Jessica Yi Hui Foo, Howard Yang, Sze Yan Tay, Way Inn Koay, King Fan Yip, Simon Kang Seng Ting, Kaavya Narasimhalu, Weishan Li, Congyuan Tan, et al.

    Undiagnosed cognitive impairment is a pervasive global issue, often due to subtle nature of early symptoms, necessitating the use of brief cognitive tests for early detection. However, most brief tests are not scalable (requiring trained professionals), and are not designed for lower literacy groups (e.g. in underserved communities). Here, we developed PENSIEVE-AITM, a drawing-based digital test that is less dependent on literacy, and can be self-administered in Pcomparison = 1.000). Results were consistent even across education subgroups. Being less dependent on literacy, PENSIEVE-AI holds promise for broader deployment in literacy-diverse populations similar to Singapore (e.g. some Asian and lower- and middle-income countries), potentially improving early detection and intervention of cognitive impairment.


  • Open Access

    Frontal Variant Alzheimer’s Disease or Primary Psychiatric Disorder? A Case Report

    by Siew Fai Liew, Weishan Li

    Background and Clinical Significance: In our case study, the patient experienced approximately a year-long delay in her diagnosis, where her initial diagnosis was mistakenly a primary psychiatric disorder, resulting in undue stress on her family. The aim of this case study is to raise awareness of frontal variant Alzheimer’s dementia (fvAD) and to increase knowledge amongst clinicians about this disorder, its management and the need for long-term follow up in specialized clinics. Case Presentation: In January 2023, a 56-year-old woman first presented with a 4-month history of worsening cognitive symptoms with considerable overlapping mood symptoms. Her Mini-Mental State Examination (MMSE) score was 20/28, whereas her Frontal Assessment Battery (FAB) score was 6/18. Upon neuropsychological evaluation, she demonstrated multidomain cognitive deficits, where impairments were most prominent in executive dysfunction, learning, memory and semantic fluency. There was evidence of progressive neurodegenerative changes, with brain MRI (April 2024) showing predominant bilateral frontal and parietal volume loss, sparing the occipital and temporal lobes. Amyloid positron emission tomography (PET) was diffusely positive. A diagnosis of fvAD (frontal variant Alzheimer’s dementia) with BPSD was made. Other differential diagnoses included a major neurocognitive disorder due to multiple etiologies (AD and dementia with Lewy bodies (DLB)), frontotemporal dementia (bvFTD), primary progressive aphasia (PPA) and the psychiatric disorder of pseudodementia secondary to a mood disorder. Conclusions: This case presented significant challenges given the atypical neuropsychological profile and the complexity of the symptom presentation with significant neuropsychiatric overlay. The preliminary research findings underscore the complexity of fvAD, warranting future research using fundamental approaches.